You are here: Industry Insights > Wuxi Biologics

News List

WuXi Biologics Completes Biologics Mfg. Facility in Ireland contractpharma
March 12, 2020
Designed to adopt both large scale commercial manufacturing using disposable bioreactors and next-gen continuous bioprocessing manufacturing technology.
WuXi Biologics Completes Weather-Tight Seal of its Biologics Manufacturing Facility in Ireland Wuxi Biologics
March 11, 2020
WuXi Biologics announced that it has completed the weather-tight seal of its biologics drug substance manufacturing facility on the Dundalk Campus in Ireland on schedule, which significantly symbolizes the start of the company’s global biomanufacturing ne
WuXi Biologics, Vir Biotech Partner to Develop COVID-19 Antibodies contractpharma
March 03, 2020
WuXi Biologics will conduct cell-line development, process and formulation development, and initial manufacturing for clinical development.
WuXi Biologics and Vir Biotechnology Announce Collaboration for Global Development of Antibodies to Treat COVID-19 Wuxi Biologics
February 26, 2020
WuXi Biologics and Vir Biotechnology, Inc. announced a development and manufacturing collaboration to advance and produce human monoclonal antibodies for the potential treatment of Coronavirus Disease 2019 (COVID-19), a disease caused by Severe Acute Resp
WuXi Biologics Congratulates Immutep on Positive Interim Data for IMP-321 Wuxi Bioologics
February 24, 2020
WuXi Biologics congratulates its strategic partner Immutep on the positive interim data from the company’s ongoing Phase II TACTI-002 study.
WuXi Biologics’ Subsidiary WuXi Vaccines Signed Long-Term Vaccine Manufacturing Contract with a Global Vaccine Leader Wuxi Biologics
February 19, 2020
WuXi Vaccines has entered into a strategic partnership with a global vaccine leader and signed a 20-year vaccine manufacturing contract valued approximately $3 billion USD.
WuXi Biologics Provides Back-to-work Operation Update Related to the Coronavirus Outbreak prnasia
February 12, 2020
We do not operate in Wuhan and do not have major suppliers from Wuhan. Supplies for labs and manufacturing are not likely affected.
WuXi Biologics Enables Development of Multiple Neutralizing Antibodies for Novel Coronavirus PharmaSources/Wuxi Biologics
January 29, 2020
WuXi Biologics has stepped up its efforts in enabling the development of multiple neutralizing antibodies for Novel Coronavirus (2019-nCoV) with its integrated technology platforms.
WuXi Biologics to acquire drug manufacturing plant in Germany pharmaceutical-technology
January 19, 2020
WuXi Biologics has signed an acquisition agreement to take over a Bayer’s drug product manufacturing plant in Leverkusen, Germany. The Leverkusen plant will be the Chinese firm’s first drug product facility in Europe bolstering its commercial manufacturin
WuXi Biologics and Bayer Enter into an Acquisition Agreement on a Drug Product Plant in Germany(1) PharmaSources/Wuxi Biologics
January 16, 2020
WuXi Biologics will be the back-up manufacturer for Kovaltry™ of Bayer

Previous page 1 2 3 4 5 6 7 8 9 10 Next page